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SHIFTING THE PARADIGM IN RADIATION SAFETY
Mohan Doss  Fox Chase Cancer Center
 The current radiation safety paradigm using the linear no-threshold (LNT) model is
based on the premise that even the smallest amount of radiation may cause mutations
increasing the risk of cancer. Autopsy studies have shown that the presence of cancer cells
is not a decisive factor in the occurrence of clinical cancer. On the other hand, suppres-
sion of immune system more than doubles the cancer risk in organ transplant patients,
indicating its key role in keeping occult cancers in check. Low dose radiation (LDR) ele-
vates immune response, and so it may reduce rather than increase the risk of cancer. LNT
model pays exclusive attention to DNA damage, which is not a decisive factor, and com-
pletely ignores immune system response, which is an important factor, and so is not sci-
entifically justifiable. By not recognizing the importance of the immune system in cancer,
and not exploring exercise intervention, the current paradigm may have missed an oppor-
tunity to reduce cancer deaths among atomic bomb survivors. Increased antioxidants
from LDR may reduce aging-related non-cancer diseases since oxidative damage is impli-
cated in these. A paradigm shift is warranted to reduce further casualties, reduce fear of
LDR, and enable investigation of potential beneficial applications of LDR.
Keywords: Radiation safety, Low dose radiation, LNT model, Immune system, Antioxidant stimula-
tion, Aging-related diseases
INTRODUCTION
Whereas the carcinogenic nature of high dose radiation is well estab-
lished, the health effects of low dose radiation are still being debated.
The current radiation safety paradigm is based on the linear no-threshold
(LNT) premise that even the smallest amount of radiation may cause
DNA damage and mutations increasing the risk of cancer. An analysis of
the historical foundation of the LNT model shows that the no-threshold
model was adopted in the 1950s due to carcinogenic concerns following
the observation of excess leukemias in atomic bomb survivors, but with-
out much supporting data at low doses since most of the radiobiological
data available at the time was for high doses, e.g. observed increase in
leukemias in atomic bomb survivors and observed increase in mutations
in drosophila subjected to radiation (Calabrese, 2009). The decision to
adopt the LNT model may also have been influenced by the political
movements of that time period to stop the development of nuclear
weapons (Jaworowski, 2010b). Recent measurements have shown a U-
shaped dose response curve for X-ray induced mutations in drosophila
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(Ogura et al., 2009; Koana and Tsujimura, 2010) invalidating one of the
original justifications for adopting the LNT model.
The use of a no-threshold model results in efforts and expenditures
that generally do not reduce cancer incidence significantly, but may
increase it. Cancer incidence is known to be affected by many factors,
with some factors that increase the risk, e.g. smoking (Hymowitz, 2011),
obesity (Basen-Engquist and Chang, 2011), alcohol (Testino et al., 2011),
and infection (Sell, 2011), and other factors that decrease the risk, e.g.
physical activity (Alberts et al., 2008) and vaccination (Frazer et al., 2011).
The effect of such factors on cancers can be quite significant. An estimate
of the fraction of cancers that can be attributed to sub-optimal past expo-
sures of 14 lifestyle and environmental risk factors indicates 42.7% of can-
cers in the UK in 2010 may be attributed to these factors (Parkin et al.,
2011). Such analysis can enable us to design an optimum allocation of
available resources among the different risk factors in order to maximize
the overall reduction of cancers. The use of a no-threshold model for one
of the factors can result in a lopsided allocation of resources to remedy
that factor to an extreme level, resulting in a large deviation from this
optimum allocation of resources and hence leading to a sub-optimal
reduction in cancers. Thus, using a no-threshold model for remedying a
carcinogenic factor is in general not a conservative approach.
Though these general arguments invalidate the use of a no-threshold
model for low dose radiation (and other carcinogens), the LNT model
has become firmly established in radiation protection policies around the
world. Recent reports from advisory bodies such as International
Commission on Radiological Protection (ICRP, 2007), National Research
Council (NRC, 2006) and National Council on Radiation Protection &
Measurements (NCRP, 2001) have re-affirmed the use of the LNT model.
There is continuing support for the use of the LNT model in publications
(Nussbaum, 1998; Kellerer, 2000; Preston, 2003; Martin, 2005; Brenner
and Sachs, 2006; Little et al., 2009). The government regulatory agencies
continue to use the LNT model for regulatory purposes, generally fol-
lowing the guidelines set by the above advisory bodies.
The support for the use of the LNT model is however not universal.
The validity and wisdom of using the LNT model has been questioned by
many scientists over the years, because of radiobiological data that is
inconsistent with the LNT model, e.g. (Luckey, 1980; Hickey et al., 1983;
Luckey, 1991; Thomas, 1994; Jaworowski, 1997; Cohen, 2002;
Feinendegen, 2005; Cook and Calabrese, 2006; Cohen, 2007; Mitchel,
2007; Jaworowski, 2008; Scott, 2008; Averbeck, 2009; Cuttler and
Pollycove, 2009; Tubiana et al., 2009; Jaworowski, 2010a; Sanders, 2010;
Calabrese, 2011; Scott, 2011). The French Academy of Sciences has rec-
ommended that the possibility of beneficial effects of low dose radiation
should be investigated (Tubiana, 2005). A re-evaluation of the current
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approach to radiation safety has been recommended (Mitchel, 2007) and
an alternative radiation safety approach has been proposed that raises rec-
ommended dose limits considerably from the present values (Allison,
2011). Some scientists have even suggested utilizing the hormetic effects
(e.g. cancer preventive effects) of low dose radiation, taking a stand com-
pletely opposite to that of the current radiation safety paradigm (Hickey et
al., 1983; Luckey, 1991; Cook and Calabrese, 2006). Reduction of many
diseases and conditions has been reported from the use of low dose radi-
ation in controlled animal studies, e.g. chemical induced brain damage
(Kojima et al., 1999), metastasis (Hashimoto et al., 1999), autoimmune dis-
eases (Tanaka et al., 2005), thymic lymphoma (Ina et al., 2005), diabetes
(Nomura and Sakai, 2006), atopic dermatitis and tumor metastasis
(Takahashi and Kojima, 2006), collagen-induced arthritis (Nakatsukasa et
al., 2008), tumor growth (Hayase et al., 2008), diabetes related nephropa-
thy (Nomura et al., 2011), diabetes related cardiac damage (Zhang et al.,
2011), prion infection in brain (Plews et al., 2010), and atherosclerosis
(Mitchel et al., 2011). Human studies have also shown reduction of some
diseases using low dose radiation, e.g. hypertension, diabetes, and pain
(Yamaoka and Komoto, 1996), bronchial asthma (Mitsunobu et al., 2003),
degenerative joint and spine diseases (Becker, 2004), and rheumatic dis-
eases (Falkenbach et al., 2005). The current vast difference of opinion in
the scientific community on the health effects of low dose radiation in
humans may be resolved by performing prospective studies. Considering
the current radiation safety regulations based on the LNT model, and the
fear of low dose radiation among the general public, such studies in
humans are not feasible. If the reported beneficial effects of low dose radi-
ation are true, the current paradigm may be causing considerable harm to
human health by preventing the study of these effects. Thus, it is impor-
tant to evaluate the validity of the current radiation safety paradigm.
In this paper, arguments will be presented to justify a paradigm shift
in radiation safety by showing that the present radiation safety paradigm
has fundamental flaws and so is not scientifically justifiable, has likely led
to missed opportunities in reducing cancer deaths among atomic bomb
survivors, has prevented the study of beneficial effects of low dose radia-
tion, and has likely prevented progress in reducing aging-related diseases
including cancer.
FUNDAMENTAL FLAWS OF THE CURRENT RADIATION SAFETY
PARADIGM
Exclusive attention to mutations as the cause of cancer.
The basic premise of the current radiation safety paradigm and the
consequent LNT model is that even a single ray of ionizing radiation can
result in a base change leading to a mutation that could cause cancer
(Hall and Giaccia, 2006). How important are mutations in the pathogen-
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esis of clinical cancer?
Figure 1A shows the percentage of patients having cancer cells (muta-
tions indicative of cancer) as determined from full body autopsies in a
geriatric hospital in Japan during 1982-1994 (Imaida et al., 1997). It is
seen that the percentage of patients having cancer cells is ~40% and is rel-
atively unchanged for the age ranges covering 48 to 94 years. The cancer
mortality rate for a similar age range in Japan has on the other hand
increased by a factor of ~10 (see Fig. 1B) (WHO, 2011), indicating that
the presence of cancer cells is not a decisive factor in the occurrence of
clinical cancer.
A similar pattern is seen in an autopsy study of Hungarian men (Soos
et al., 2005), where the percentage of patients having prostate cancer cells
has increased by a factor of ~2 between the ages of ~50 and ~70 whereas
the prostate cancer mortality rate has increased by a factor of ~38
between these ages (WHO, 2011). A third example is that in a recent
review, the presence of occult cancer is reported to be quite high for can-
cers of the prostate (30-70%), thyroid (36-100%), and breast (7-39%) for
specified age groups, whereas the lifetime risk of death or metastatic dis-
ease from these cancers is quite low at 4%, 0.1%, and 4% respectively
(Welch and Black, 2010). These examples show that mutations, though
essential, are not the determinant factors in clinical cancer.
Ignoring the influence of immune system response in carcinogenesis
A second feature of the current radiation safety paradigm is that it
completely ignores the effects of the different bodily defense mechanisms
in estimating the cancer risk from low dose radiation. Let us consider the
importance of immune system response (which is just one of the body’s
defense mechanisms) in the occurrence of clinical cancer. The incidence
of cancers in kidney disease patients has been estimated at various stages
of their disease treatment (Vajdic and van Leeuwen, 2009a). The cancer
incidence for kidney transplant patients (in whom the immune system
was suppressed) was observed to be higher by a factor of ~2.4 in compar-
ison to kidney dialysis patients, indicative of the importance of the
immune system in keeping the occult cancers in check. This increase
included not only cancers known to be caused by viruses, but also cancers
not viral in origin. The immune system can play a key role in maintaining
cancers in an equilibrium state preventing occult cancers from becoming
clinical cancers (Koebel et al., 2007). If the immune system were sup-
pressed in the general population, and resulted in an increase in cancer
similar to kidney transplant patients (i.e. by a factor of ~2.4), essentially
the whole population would face clinical cancer, since the lifetime risk of
cancer incidence is ~40%. What appears to separate those who have can-
cer from those who do not is not the presence of cancer cells (or car-
cinogenic viruses) but the immune system response. The increased risk of
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FIGURE 1A. Percentage of patients from a geriatric hospital in Japan who had cancer as determined
by autopsy during 1982-1994, as a function of age. Data from (Imaida et al., 1997). 
FIGURE 1B. Cancer mortality rate per 100,000 in Japan as a function of age (WHO, 2011). 
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cancer from immune suppression in organ transplant patients was report-
ed more than forty years ago (Allison, 1970).
A considerable amount of additional evidence is available indicative of
the importance of the immune system response in modulating the car-
cinogenic process. AIDS patients, whose immune system is suppressed, also
have higher levels of cancer incidence in a manner similar to kidney trans-
plant patients (Vajdic and van Leeuwen, 2009b). The age-related decline in
immune system (Weinberger et al., 2008) may be mainly responsible for the
age-related increase in cancer incidence rather than the mutations (Jones,
2011). Increase in lung cancer and other cancers among smokers is attrib-
uted to the adverse effect of cigarette smoke on the immune system
(Stampfli and Anderson, 2009). The lower immune response may also be
responsible for the higher recurrence rate of prostate cancer and poorer
survival among smokers (Kenfield et al., 2011a).
Since suppression of the immune system has been observed to corre-
late with increased cancers, it would be logical to infer that improving the
immune system response may reduce the cancer incidence. Moderate
exercise is known to stimulate the immune system (Martin et al., 2009)
and is known to reduce the incidence of many types of cancers
(Warburton et al., 2006; John et al., 2010). Higher immune response is
correlated with longer survival in pancreatic cancer patients (Hamanaka
et al., 2003). An overactive immune system as indicated by allergies has
been associated with reduced incidence of some types of cancers and
overall cancer rates (Wang and Diepgen, 2005). Increased immune
response was indicative of lower ovarian cancer risk in a prospective study
(Pinheiro et al., 2010). Success has been reported in treating cancers with
immunotherapy, e.g. with Ipilimumab, which improves the immune
response by overcoming T-cell suppression (Weber, 2007).
All these data point to an extremely important role played by defi-
ciencies in the immune system in the pathogenesis of clinical cancer, with
oncogenic mutations in the cancer cells playing an essential but not the
decisive role. The immune system is however not a perfect defense
against cancer, and cancer can develop in spite of the fully functioning
immune system (Dunn et al., 2004). The LNT model completely ignores
the immune system response in its estimation of cancer risk.
Since the immune system is so crucial in modulating the carcinogenic
process, let us consider how radiation affects the immune system. Low
dose radiation has been observed to stimulate the immune system
(Hashimoto et al., 1999; Yu et al., 2004; Ina et al., 2005; Liu, 2007). Low
dose radiation also stimulates other aspects of the bodily defense mecha-
nisms, e.g. it increases antioxidant levels reducing the endogenous DNA
damage, increases DNA repair capacity, and increases apoptosis of dam-
aged cells (Feinendegen, 2005). High dose radiation, on the other hand,
Shifting the Paradigm in Radiation Safety
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suppresses the immune capacity (Kennedy, 1965; Anderson and
Lefkovits, 1979; Celer, 1990; Liu, 2003; Kusunoki and Hayashi, 2008).
An analogy with exercise may be helpful in understanding the bipha-
sic dose response of the immune system to radiation. Whereas moderate
exercise is known to stimulate the immune system, extreme exercise has
an immune suppressive effect (Nieman, 2003; Radak et al., 2008; Martin
et al., 2009). The benefits of moderate exercise in reducing the incidence
of many diseases including cancer have been well documented
(Warburton et al., 2006). For patients diagnosed with breast cancer and
prostate cancer, vigorous physical activity has been linked to decreased
mortality from the diseases (Holick et al., 2008; Kenfield et al., 2011b). On
the other hand, extreme exercise such as marathon or ultra-marathon
running is associated with increased upper respiratory tract infections
indicative of the suppression of the immune system (Peters and Bateman,
1983), and increased intensity of training is associated with an increased
number of melanoma markers in marathon runners (Richtig et al., 2008).
Ignoring the large variation in cancer rates in specifying no threshold.
A third aspect of the current radiation safety paradigm and the con-
sequent LNT model is that even the smallest dose of radiation is claimed
to increase the risk of cancer, as there is no threshold. Meaningful meas-
urement of the small predicted increase in cancer from the low dose radi-
ation would be possible only if the cancer rates are stable, and have small
measurement errors. It is well known that cancer incidence rates are
highly variable as they depend on a large number of factors including
age, tobacco use, ionizing radiation, chemicals, infections, alcohol, diet,
exercise, etc. Separating the effect of one factor such as radiation in the
presence of all the other variables would be subject to large errors and
uncertainties. The measured cancer incidence rate is also affected by the
sensitivity of the technologies used for screening for different types of
cancers, and the extent of the screening. Over short periods of time most
of these variables may be expected to have changed by a smaller amount.
Hence, we may be able to obtain an indication of the stability of the can-
cer rates and uncertainties in their measurements by studying differences
in cancer rates between successive years.
The Surveillance, Epidemiology, and End Results (SEER) Program of
the National Cancer Institute collects and publishes cancer incidence
data from population-based cancer registries covering a large segment of
the population in the USA (Altekruse et al., 2010). A large variation
(much higher than standard errors) has been observed in the SEER age-
adjusted cancer incidence rates between successive years, ranging from 
-3.4% to +4.5% (See Fig. 2). This variation is indicative of the effect of the
multiple factors that can change the cancer rates between successive
years. When calculating the lifetime risk of cancer for any cohorts, these
M. Doss
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variations can compound and become substantial. Hence there can be
large uncertainties in estimating low dose cancer risk factors from car-
cinogens like radiation using long term studies. Indeed, the 95% confi-
dence interval (C.I.) of cancer risk factor for low dose radiation spans a
wide range of 400 to 1600 excess solid cancers per 100 mSv per 100,000
(for males), in the recent BEIR VII report (NRC, 2006). The uncertainty
in the recommended risk factor has actually worsened when compared to
the range of 420 to 1040 given in the BEIR V report (for 90% C.I.) 16
years earlier (NRC, 1990). Such a large and increasing uncertainty in the
basic parameter of the LNT model after more than fifty years of study
indicates the relationship between low dose radiation and cancer is very
tenuous indeed, and low dose radiation may not be a relevant factor in
carcinogenesis.
In the above analysis, I have described three fundamental flaws of the
current radiation safety paradigm:
1. The paradigm pays exclusive attention to DNA damage and mutations
which are not decisive factors in clinical cancer.
Shifting the Paradigm in Radiation Safety
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8
Dose-Response: An International Journal, Vol. 10 [2014], Iss. 4, Art. 12
https://scholarworks.umass.edu/dose_response/vol10/iss4/12
2. The paradigm completely ignores the effect of the immune system
response which is an extremely important factor modulating the
occurrence of clinical cancer. The effect of radiation on immune sys-
tem response is not linear, as low dose radiation stimulates the
immune system, and high dose radiation suppresses it.
3. The paradigm and the consequent LNT model ignore the large vari-
ability in cancer rates in specifying no threshold. The lifetime risk
measurements are likely to have large errors arising from the vari-
ability in the confounding factors and cancer rates from year to year.
In view of this, specifying no threshold and implying that the smallest
calculated increment in cancer rate is significant, is not credible.
Notwithstanding these fundamental flaws, we have been using the
current radiation safety paradigm during the past five decades to guide us
in our use of radiation. Were there any adverse health consequences from
following this flawed paradigm?
FAILURE OF THE CURRENT RADIATION SAFETY PARADIGM
Our current radiation safety paradigm (exclusive attention to muta-
tions, and ignoring the importance of bodily defense mechanisms includ-
ing the immune system, as signified by the adoption of the LNT extrapo-
lation model) may have led to missed opportunities in reducing cancer
deaths in populations exposed to high doses of radiation such as the
atomic bomb survivors in Japan. The importance of the immune system
in holding cancers in check was noted as early as the 1970s, from the
observed dramatic increase in cancers in organ transplant patients whose
immune systems were suppressed, e.g. (Allison, 1970; Hoover and
Fraumeni, 1973). The effect of exercise on enhancing different aspects of
the immune system has been known for more than a century (Gleeson,
2000). Increased exercise had been correlated with decreased growth of
tumors in animal models (Rusch and Kiline, 1944; Rashkis, 1952;
Newton, 1965). Improved immune response (leukocytosis) from exercise
had been observed in atomic bomb survivors (Belsky et al., 1972).
Therefore, data was available in the 1970s to infer the beneficial effects of
exercise in improving the immune system response and in reducing can-
cer. However, during this period, radiation-induced mutations became
the primary focus in the carcinogenic process as signified by the domi-
nance of the LNT model in radiation safety policies. The possibility of
reducing cancers in the atomic bomb survivors through lifestyle modifi-
cation (by educating them on the importance of the immune system and
encouraging more physical exercise) was missed. A recent prospective
study of the effects of lifestyle on cancer among atomic bomb survivors
has shown that the group that exercised had between 15% and 35% less
cancer mortality with 95% confidence compared to the group that did
M. Doss
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not exercise, indicating the effectiveness of exercise in reducing cancers
in this population group (Mine et al., 2011). If we had conducted a study
such as this in the 1970s, demonstrated the importance and effectiveness
of exercise in reducing cancers, and initiated an education and support
program for the atomic bomb survivors to exercise regularly, it may have
resulted in significantly decreased cancer incidence and mortality in the
radiated population. Instead, the LNT model has led us to a fatalistic and
pessimistic approach towards population groups subjected to high doses
of radiation, where we monitor their health closely, but take little action
to reduce their risk of developing clinical cancer, for example by boost-
ing their immune system with exercise. It is ironic that lack of action due
to our radiation safety paradigm may have resulted in increased cancer
deaths in the most radiated population group, whom the radiation safety
paradigm should have protected. The radiation safety paradigm may have
failed in its primary responsibility of protecting the health of the radiat-
ed population. It is imperative we consider a shift in the current radiation
safety paradigm to include consideration of biological defense mecha-
nisms in order to reduce further casualties in population groups that
have been subjected to high dose radiation. Exercise intervention should
be prescribed to the atomic bomb survivors and other radiated popula-
tion groups (e.g. Chernobyl liquidators) to reduce their cancer risk in a
pilot study, and if the intervention is found to be beneficial, should be
expanded to the whole group. A shift in the present radiation safety par-
adigm can also enable study of the many reported beneficial effects of low
dose radiation.
POTENTIAL BENEFICIAL EFFECTS OF LOW DOSE RADIATION
The biological effects of low dose radiation have been found to be
similar to that of moderate exercise in animal studies, in that they stimu-
late the production of antioxidants (Yamaoka et al., 1991; Kojima et al.,
1999; Khassaf et al., 2001; Ji, 2002), have a similar effect on cancer-initia-
tion related parameters such as DNA damage, double-strand breaks, and
apoptosis, (De Lisio et al., 2011; Phan, 2011), and enhance the immune
system response (Nieman, 2003; Farooque et al., 2011). Several different
classes of beneficial health effects of low dose radiation may be envi-
sioned based on these observed biological effects.
The first class of potential beneficial effects of low dose radiation is its
cancer preventive or therapeutic effect, since low dose radiation stimu-
lates the bodily defense mechanisms including the immune system
(Feinendegen, 2005). Low dose radiation has been observed to have a
cancer preventive effect in controlled animal studies (Ullrich and Storer,
1979; Ito et al., 2007; Nowosielska et al., 2010; Phan, 2011). Low dose radi-
ation has been shown to be an effective method of treating cancer by
boosting the immune system in animal and human studies with little
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adverse side effects (Sakamoto, 2004; Farooque et al., 2011). Several ret-
rospective human studies have shown a reduced cancer incidence from
low dose radiation, however such studies are subject to many confound-
ing factors, and so they are not discussed here. Prospective cancer pre-
vention studies have been suggested (Cameron, 2002) but would require
subjecting an asymptomatic population group to low dose radiation to
measure the change in cancer rates. Considering the present radiation
safety regulations and the widespread fear of radiation, such a prospective
study is neither feasible nor advisable.
A second class of beneficial effects of low dose radiation may be in the
control of aging-related non-cancer diseases. Oxidative damage has been
implicated in the pathogenesis of many of these aging-related diseases
and conditions, e.g. Alzheimer’s disease (Martins et al., 1986; Bonda et al.,
2010), arthritis (Vasanthi et al., 2009), cataract (Spector, 1995), diabetes
(Henriksen et al., 2011), heart disease (Heitzer et al., 2001), osteoporosis
(Baek et al., 2010), Parkinson’s disease (Zhang et al., 1999), and stroke
(Nanetti et al., 2011). Elevating antioxidant levels in the relevant organs
may be helpful in reducing the oxidative damage and the impact of such
diseases. In animal models, increased amount of antioxidants has led to
a reduction of some of the non-cancer diseases, e.g. (Jung et al., 2001;
Redout et al., 2010). Application of this idea in humans has however been
problematic. Antioxidant therapies have failed to reduce diabetes
(Sheikh-Ali et al., 2011), cardiovascular disease (Kris-Etherton et al., 2004)
and stroke (Schurks et al., 2010) in controlled clinical trials, though
oxidative damage has been identified as playing a key role in these.
Bioavailability of the antioxidants in the relevant organs may be a factor,
as the administered antioxidants are distributed throughout the body.
Increased administration of antioxidants may be considered for improv-
ing bioavailability. However, excessive levels of antioxidants can interfere
with essential cellular signaling mechanisms and so may be harmful
(Halliwell, 2011). Use of antioxidants more than seven times per week
has been associated with a doubling of prostate cancer risk when com-
pared to the population not using any antioxidant supplements in a large
study (Lawson et al., 2007). Antioxidant supplements have been observed
to prevent the health-promoting effects of exercise (Ristow et al., 2009).
A compilation of a large number of randomized clinical trials on the
effects of antioxidant supplements has shown a slight increase in mortal-
ity in the groups using antioxidant supplements (Bjelakovic et al., 2007).
Whereas externally administered antioxidants have been observed to not
be beneficial and potentially harmful, endogenous production of antiox-
idants, such as from moderate exercise, has been found to be beneficial
(Briones and Touyz, 2009).
Low dose radiation is known to elevate the antioxidant levels in many
organs in animal studies, e.g. (Yamaoka et al., 1991; Kojima et al., 1999;
M. Doss
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Pathak et al., 2007), and so may play a role in reducing the impact of the
diseases and conditions caused by oxidative damage. Animal studies have
shown low dose radiation reduces several non-cancer diseases, e.g. dia-
betes and diabetes related complications (Nomura and Sakai, 2006; Wang
et al., 2008; Nomura et al., 2011), autoimmune diseases (Tanaka et al.,
2005), arthritis (Nakatsukasa et al., 2008), brain injury from chemical
induced oxidative damage (Kojima et al., 1999) and prion infection in the
brain (Plews et al., 2010). Human studies with low dose radiation have
also shown a reduction in some non-cancer diseases, e.g. asthma
(Mitsunobu et al., 2003), and rheumatic diseases (Falkenbach et al.,
2005). Reduced non-cancer mortality has been reported in atomic bomb
survivors exposed to low dose radiation for the period 1950-67 (but not
in a later period) indicative of a non-cancer disease preventive effect of
low dose radiation in the near term (Preston et al., 2003; Luckey, 2008).
In a study of fluorspar miners exposed to high dose radiation to the lungs
from radon, the miners had higher mortality from lung cancer as expect-
ed, but the standardized mortality ratio for non-cancer diseases was 0.74
(95% CI: 0.70-0.77) (Villeneuve et al., 2007). Thus, there is suggestive evi-
dence in epidemiological studies for the beneficial effect of low dose radi-
ation for non-cancer diseases. Considering that currently there is no
method of preventing, curing or controlling some of these diseases (e.g.
Alzheimer’s), the effect of low dose radiation on the non-cancer diseases
should be studied systematically, to determine if low dose radiation has a
beneficial effect for any of these diseases. The beneficial effects may
become evident in a short period of time in terms of reduced sickness
and mortality. By not studying the health effects of low dose radiation sys-
tematically because of the LNT model based fear, we may have missed an
opportunity to reduce non-cancer diseases.
A third class of beneficial effects of low dose radiation may be the
reduction of adverse side effects of standard cancer therapies. Radiation-
induced free radicals and the oxidative damage they cause are predomi-
nantly responsible for the biological damage and adverse side effects
from the high-dose radiation used in radiotherapy (Lawenda et al., 2008).
Likewise, for many chemotherapy agents, oxidative damage to normal tis-
sues is responsible for the adverse effects (Chen et al., 2007). Elevating
the level of antioxidants in the normal tissues prior to the cancer thera-
pies may be helpful in reducing the damage and the side effects.
However, systemic administration of antioxidants may reduce the effec-
tiveness of the therapies, and so is not recommended (Lawenda et al.,
2008). The advantage of low dose radiation is that it can be applied selec-
tively to normal tissues while minimally exposing the tumors, thus limit-
ing the primary adaptive response to normal tissue only. For example,
prior low dose radiation of normal cells surrounding the tumor volume
has been tested in a canine model to demonstrate reduction of skin and
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mucous membrane side effects of radiation therapy by inducing an adap-
tive response in the normal cells (Blankenbecler, 2010). Another advan-
tage of using low-dose radiation is that it has been shown to stimulate the
immune system leading to improved tumor control in animal studies (Wu
et al., 2008). It may also lead to increased apoptosis of pre-cancerous cells
through inter-cellular communication (Portess et al., 2007). Thus pre-
treatment of normal tissues with low dose radiation may reduce the
adverse side effects from cancer therapies, without reducing the effec-
tiveness of the therapies, and may even enhance their effectiveness.
A fourth class of beneficial effects of low dose radiation may be to
impart the beneficial effects of exercise to persons with disabilities,
painful conditions or weakness that prevent or discourage them from
exercising. Though the benefits of appropriate exercise for such popula-
tions have been well documented, compliance with exercise programs
due to pain is a considerable problem as there are high dropout rates
(Richards and Scott, 2002).
The use of low dose radiation contrasts sharply with traditional
approaches for these illnesses and conditions. Many of the standard
drugs and treatments are effective in controlling the symptoms of the dis-
eases, e.g. coronary plaque formation, hormonal imbalance, hyperten-
sion, tumors, etc. without addressing the underlying causes of the aging-
related diseases which appear to be oxidative stress and/or deficiencies in
the immune system. Thus the diseases and the symptoms tend to recur,
e.g. blockage of arteries, second cancers, etc. Since the administered
drugs are distributed throughout the body and act on normal tissues and
organs in addition to the targeted organs, many of the drugs have serious
side effects. Standard cancer therapies also have immediate and long last-
ing adverse side effects (Cukier, 2005). Even targeted therapies can have
serious side effects when continued over a long period of time (Appleby
et al., 2011). On the other hand, low dose radiation has beneficial bio-
logical effects similar to moderate exercise, as it elevates antioxidant lev-
els and addresses the underlying cause of the diseases and conditions,
and it can be applied to any organ or tissue locally minimizing the effects
on other organs and tissues, if so desired. Low dose radiation may be use-
ful in reducing the recurrence of the diseases by reducing oxidative dam-
age after the symptoms have been addressed through traditional means.
DISCUSSION
It is clear from the discussions above that there is no justification for
continuing the use of the current radiation safety paradigm, as it was estab-
lished based on premises that have turned out to be false, is fundamental-
ly flawed, has no scientific foundation, has likely led to missed opportuni-
ties in reducing cancer deaths among atomic bomb survivors, has led to
an irrational fear of low dose radiation, has prevented the study of poten-
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tially beneficial applications of low dose radiation, and has likely prevent-
ed progress in reducing aging-related diseases, side effects of cancer ther-
apies, and diseases in the infirm. We need to shift to a paradigm that rec-
ognizes adaptive response and the potential for beneficial effects of low
dose radiation. Making this change is not going to be easy, as the new par-
adigm is contrary to the recommendations of most advisory bodies, pres-
ent government regulations, and the public perception of the effects of
low dose radiation. Any attempts to rescind the current regulations may be
viewed with suspicion by the public because of the widespread belief in the
LNT model. A sustained educational campaign should be initiated to cor-
rect the current misconceptions in the scientific community and the pub-
lic about the pathogenesis of clinical cancer and the health effects of low
dose radiation. Demonstration of beneficial health effects of low dose radi-
ation through pilot clinical trials may be helpful in reducing the fear of
low dose radiation, and enabling the paradigm shift.
To guide us in this change, the scientific community should form new
advisory bodies that use experimental evidence (including the observed
beneficial effects of low dose radiation) in recommending radiation safe-
ty policies rather than the unproven LNT extrapolation hypothesis advo-
cated by most of the present advisory bodies. Such advisory bodies can
also guide us in studying and implementing the beneficial applications of
low dose radiation.
The last paradigm shift in radiation safety occurred in the 1950s.
Prior to this period, the main concern with radiation use was skin ery-
thema (Sinclair, 1981), and it was considered as appropriate to treat many
diseases and conditions with radiation, including for children, e.g.
(Mottram and Hill, 1949). In the 1950s, following the observation of
increased leukemias in atomic bomb survivors, genetic effects became
the dominant concern leading to the adoption of the current radiation
safety paradigm, as the advisory bodies such as NCRP and ICRP reduced
the radiation dose limits. This was not because of any observed harm
from low dose radiation but because of general public concerns (Sinclair,
1981). Realization that the current paradigm may have led to missed
opportunities in preventing cancer deaths among atomic bomb survivors
may again raise public concerns and scrutiny by the media, and facilitate
another paradigm shift in radiation safety in the near future.
SUMMARY AND CONCLUSIONS
The current radiation safety paradigm using the LNT model was
introduced following the observation of linear dose dependence of
leukemias in atomic bomb survivors for high dose radiation, observation
of linear dose dependence of mutations in drosophila for high dose radi-
ation, linking the two, and extrapolating linearly to low doses since can-
cer is such a feared disease. The LNT model pays exclusive attention to
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DNA damage, which is not a decisive factor in clinical cancer as observed
in autopsy studies, while ignoring the immune system response, which
plays a major role in keeping occult cancers in check, as indicated by the
huge increase in cancers in organ transplant and AIDS patients. The
large temporal and regional variations in cancer rates have been ignored
in setting a zero threshold in the LNT model, implying the smallest
changes in projected cancer rates are significant. The large expenditures
for dose reduction based on the LNT model may not result in any meas-
urable reduction in cancers. In view of the large number of factors that
have measurable effects on cancer rates, an optimum allocation of avail-
able resources between the different risk factors can result in maximizing
the reduction in cancers. The lopsided allocation of resources based on
the LNT model deviates from this optimum allocation and so would
result in a sub-optimal reduction in cancers. Thus, the use of a no-thresh-
old model is not a conservative approach to radiation safety.
Our misunderstanding of the pathogenesis of clinical cancer and the
resultant radiation safety paradigm paying exclusive attention to muta-
tions may have resulted in missed opportunities in preventing cancer
deaths in atomic bomb survivors and in other radiated populations. The
importance of the immune system in preventing cancers was known in
the 1970s from the increased cancers in organ transplant patients in
whom the immune system had been suppressed. The increase in immune
response from exercise has been known for more than a century. A
recent prospective study of the effect of lifestyle on cancers has shown the
effectiveness of exercise in reducing cancers in atomic bomb survivors.
An exercise intervention study in the 1970s could have resulted in
reduced cancer deaths among atomic bomb survivors. However, the focus
of the radiation safety paradigm in that time period was on reducing
mutations as the cause of cancer, and so missed the opportunity to reduce
cancers in this population group. The current radiation safety paradigm
has likely failed in its primary responsibility of reducing radiogenic can-
cers. A paradigm shift is warranted to reduce further casualties.
The biological effects of low dose radiation are similar to that of mod-
erate exercise in that they both lead to slightly increased production of
free radicals stimulating the body’s defensive mechanisms such as
increased antioxidant capacity and the immune system. Thus, low dose
radiation may be expected to reduce rather than increase cancers, since
the immune system plays an extremely important role in preventing can-
cers. This has been observed in many controlled animal studies. The
increased antioxidants may also help to reduce aging-related diseases
since oxidative damage has been implicated in many of these diseases.
External administration of antioxidants has failed to reduce diseases in
clinical trials, possibly because there may not have been sufficient
bioavailability of the antioxidants in the relevant organs to reduce the
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oxidative damage. Administration of large doses of antioxidants can
interfere with important cellular signaling mechanisms, resulting in wors-
ening of health and so is not recommended. Thus we are at an impasse
in dealing with the underlying cause of aging-related diseases. Low dose
radiation may provide a solution to this impasse by endogenous produc-
tion of antioxidants in the relevant organs. Controlled animal studies
have shown reduction of many of these diseases using low dose radiation,
and some human studies have also shown promising results. Low dose
radiation can be used to supplement traditional treatments which address
the symptoms of the diseases, in order to reduce the recurrence of the
diseases. The increased antioxidants from low dose radiation may also
reduce the adverse side effects of cancer therapies, since many of these
are caused by oxidative damage also. Another potential application of low
dose radiation may be in providing the benefits of exercise to the infirm
that are unable to exercise.
The current situation with respect to these different diseases and con-
ditions is far from satisfactory, as there is no effective way to prevent the
cancers, aging-related diseases such as Alzheimer’s, adverse side effects of
cancer therapies, and inactivity related diseases in the infirm. Pilot clinical
trials should be conducted to study the effects of low dose radiation for
these diseases and conditions to identify the beneficial ones for potential
use. The current radiation safety paradigm and regulations, and the con-
sequent fear of low dose radiation have discouraged such studies, prevent-
ing progress in dealing with these unsolved problems in human health.
A paradigm shift is warranted to reduce further casualties and
improve human health. Since the proposed changes are completely con-
trary to the recommendations of most of the current advisory bodies, it
may be preferable to form new advisory bodies with a fresh perspective to
guide us in these changes. Realization by the media and the public that
the present paradigm, by its inaction, may have missed opportunities in
reducing cancer deaths among radiated populations may lead to
increased public concerns and closer scrutiny, and hasten the process of
dismantling the current radiation safety paradigm in the near future.
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